医学
前列腺癌
谷氨酸羧肽酶Ⅱ
核医学
复发性前列腺癌
癌症
生化复发
PET-CT
内科学
正电子发射断层摄影术
前列腺切除术
作者
Lucia Baratto,Hong Song,Heying Duan,Negin Hatami,H.P. Bagshaw,Mark K. Buyyounouski,Steven Hancock,Sumit Shah,Sandy Srinivas,Patrick S. Swift,Farshad Moradi,Guido Davidzon,Andrei Iagaru
标识
DOI:10.2967/jnumed.120.259630
摘要
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting 68Ga-RM2 with the prostate-specific membrane antigen (PSMA)-targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients underwent both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 (n = 23) or 18F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUVmax was collected for all lesions. Results:68Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. 68Ga-PSMA11/18F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: 68Ga-RM2 detected 7 more lesions in 4 patients, whereas 68Ga-PSMA11/18F-DCFPyL detected 36 more lesions in 13 patients. Conclusion:68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI